The World Health Organization (WHO)
has revised its treatment guidelines for people living with HIV worldwide,
recommending they begin antiretroviral (ARV) therapy when their CD4 count hits
500 or below, as opposed to the previous benchmark of 350, The New York Times
reports. WHO released the new guidelines on the opening day of the
International AIDS Society 2013 conference in Kuala Lumpur.
WHO also recommended that various
subgroups of HIV-positive people receive ARVs regardless of CD4 count,
including all children younger than 5, all pregnant and nursing women, and
anyone in an ongoing relationship with an HIV-negative partner. The agency
continues to advise that all of those who are HIV positive and living with
active tuberculosis (TB) or with hepatitis B virus (HBV) receive ARVs.
A further recommendation is that all
adults should begin treatment with a once-a-day, single pill combination
therapy containing Viread (tenofovir), Sustiva (efavirenz) and either Epivir
(lamivudine) or Emtriva (emtricitabine). (Atripla contains tenofovir, efavirenz
and emtricitabine; a generic-based version of the combo uses lamivudine instead
of emtricitabine—the two meds operate similarly—and has received tentative
approval by the FDA.)
The new guidelines will extend drug
eligibility from the current 17 million to 26 million people in poor and
middle-income countries. WHO estimates that nearly 10 million people are
currently receiving ARVs worldwide, out of a total 34 million living with the
virus.
WHO projects that the new guidelines
could prevent an additional 3 million deaths as well as 3.5 million new
infections by 2025.
To read the WHO release, visit: http://www.who.int/mediacentre/news/releases/2013/new_hiv_recommendations_20130630/en/#
The Friends of AIDS Foundation is
dedicated to enhancing the quality of life for HIV positive individuals and
empowering people to make healthy choices to prevent the spread of the HIV
virus.
To learn more about The Friends of
AIDS Foundation, please visit: http://www.friendsofaids.org.
TOGETHER WE REMAIN STRONG!